The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
GlobalData on MSN4d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatmentBiogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...
News Medical on MSN8d
Gene therapy shows promise in treating SCN1B-linked epileptic encephalopathiesDravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United ...
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback